US equities
|
META
$622.60
▼-1.26%
TSLA
$406.60
▲+3.82%
MU
$931.81
▲+3.11%
NVDA
$217.54
▲+0.72%
SPCX
$149.72
▲+1.92%
AMD
$559.61
▲+5.33%
SNDK
$1,298.00
▲+3.38%
AAPL
$345.75
▲+0.54%
META
$622.60
▼-1.26%
TSLA
$406.60
▲+3.82%
MU
$931.81
▲+3.11%
NVDA
$217.54
▲+0.72%
SPCX
$149.72
▲+1.92%
AMD
$559.61
▲+5.33%
SNDK
$1,298.00
▲+3.38%
AAPL
$345.75
▲+0.54%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Parabilis Medicines, Inc. - Common Stock
(NQ:
PBLS
)
27.08
+2.05 (+8.19%)
Delayed Quote
Updated: 2:51 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Parabilis Medicines, Inc. - Common Stock
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
↗
October 24, 2026
Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology...
Via
MarketBeat
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
October 24, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
October 19, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
October 14, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 01, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
August 25, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
↗
June 27, 2026
Parabilis Medicines is ambitious, but it has Regeneron on its side already.
Via
The Motley Fool
Topics
Initial Public Offering
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
↗
June 20, 2026
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History.
↗
June 15, 2026
The Elon Musk-led company has attracted investors' attention in recent days.
Via
The Motley Fool
Topics
Artificial Intelligence
Initial Public Offering
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
↗
June 12, 2026
It's important to consider your comfort with risk before diving in.
Via
The Motley Fool
Topics
Initial Public Offering
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 11, 2026
From
Parabilis Medicines, Inc.
Via
GlobeNewswire
